| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/23/2002 | WO2001076621A3 Methods and compositions for treating neoplasms |
| 05/23/2002 | WO2001072837A3 Methods of modulating drug clearance mechanisms by altering sxr activity |
| 05/23/2002 | WO2001072826A3 Oncogenic osteomalacia-related gene 1 |
| 05/23/2002 | WO2001072707A3 Carbamate caspase inhibitors and uses thereof |
| 05/23/2002 | WO2001068866A3 Estrogen-regulated unconventional myosin-related protein: compositions and methods of use |
| 05/23/2002 | WO2001064837A8 β NETRIN AND USES THEREOF |
| 05/23/2002 | WO2001053506A3 Virus strains for the oncolytic treatment of cancer |
| 05/23/2002 | WO2001047946A9 GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR |
| 05/23/2002 | WO2001044206A9 Pyrazine based inhibitors of glycogen synthase kinase 3 |
| 05/23/2002 | WO2001042179A9 Compounds which mimic the chemical and biological properties of discodermolide |
| 05/23/2002 | WO2001041760A9 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 05/23/2002 | WO2001040271A9 Cancer associated antigens and uses therefor |
| 05/23/2002 | WO2000071121A9 Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations |
| 05/23/2002 | WO2000063204A3 Substituted azoles |
| 05/23/2002 | US20020062031 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| 05/23/2002 | US20020062023 Palau'amine; treatment of tumors, fungal infections and immunosuppressive affections. |
| 05/23/2002 | US20020061929 Composition and method containing products extracted from commiphora sp. for prevention and treatment of abnormal cell growth and proliferation in inflammation, neoplasia and cardiovascular disease |
| 05/23/2002 | US20020061923 Diacid isoindoleine amide derivative |
| 05/23/2002 | US20020061922 Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
| 05/23/2002 | US20020061920 Selected fused pyrrolocarbazoles |
| 05/23/2002 | US20020061914 Benzothiazole, benzooxazole and benzoimidazole derivatives as sodium or calcium channel modulators |
| 05/23/2002 | US20020061911 Enantiomers of 6-amino EM-12 and method of use |
| 05/23/2002 | US20020061909 Vitronectin receptor antagonist pharmaceuticals |
| 05/23/2002 | US20020061905 Ethers of 7-desmethylrapamycin |
| 05/23/2002 | US20020061904 Hydroxyesters of 7-desmethylrapamycin |
| 05/23/2002 | US20020061877 Substituted cyclic amine metalloprotease inhibitors |
| 05/23/2002 | US20020061873 Having high bioavailability levels and reduced variability of bioavailability by use of dispersed, colloidal structures, colloids or analogous structures of the drug, a hydrophilic component, and a surfactant |
| 05/23/2002 | US20020061871 Photochemotherapeutic compositions |
| 05/23/2002 | US20020061868 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives |
| 05/23/2002 | US20020061866 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor |
| 05/23/2002 | US20020061865 Bicyclic heterocycles that inhibit cyclin-dependent kinase or tyrosine kinase enzymes, or both, for treatment of proliferative disorders |
| 05/23/2002 | US20020061860 Antisense oligonucleotide inhibition of specific histone deacetylase isoforms |
| 05/23/2002 | US20020061853 Caspase inhibtors and uses thereof |
| 05/23/2002 | US20020061846 Administering to a mammal Group B- beta hemolytic streptococci(GBS) toxin receptors or immunogenic fragments to induce an immune response to the GBS receptors for prventing pathoangiogenic conditions |
| 05/23/2002 | US20020061843 Use of mCRP for delivery of materials into cells |
| 05/23/2002 | US20020061834 Human G-protein Chemokine receptor (CCR5) HDGNR10 |
| 05/23/2002 | US20020061543 Diagnosing cancer in humans; obtain tissue, monitor transcription factor expression, compare to control, amplified expression indicates cancer |
| 05/23/2002 | US20020061330 Supports for photosensitizer formulations |
| 05/23/2002 | US20020061316 Immunotherapeutic stress protein-peptide complexes against cancer |
| 05/23/2002 | US20020061310 Compositions and methods for dendritic cell-based immunotherapy |
| 05/23/2002 | US20020061307 Polyalkylene oxide-modified single chain polypeptides |
| 05/23/2002 | US20020061304 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 05/23/2002 | US20020061300 Method and composition for treating prostate cancer |
| 05/23/2002 | US20020061298 Method for optimally delivering virus to a solid tumor mass |
| 05/23/2002 | US20020061294 Mononuclear phagocytes in therapeutic drug delivery |
| 05/23/2002 | US20020061289 Stem cell-based methods for preventing and treating tumor |
| 05/23/2002 | DE10057443A1 Use of specific antibodies, or individual chains, for treating tumors and vascular occlusions, by inhibition of the gpIIb/IIIa receptor |
| 05/23/2002 | DE10054019A1 Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel New substituted indolinones, their preparation and their use as medicaments |
| 05/23/2002 | CA2447553A1 Saframycins, analogues and uses thereof |
| 05/23/2002 | CA2429897A1 M. tuberculosis chaperonin 10 and uses thereof |
| 05/23/2002 | CA2429894A1 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | CA2429460A1 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 05/23/2002 | CA2429455A1 Fat regulated genes, uses thereof, and compounds for modulating same |
| 05/23/2002 | CA2429437A1 Imidazole derivatives, process for their preparation and their use |
| 05/23/2002 | CA2429411A1 Texaphyrin coordination compounds and uses thereof |
| 05/23/2002 | CA2429342A1 Promoters exhibiting endothelial cell specificity and methods of using same |
| 05/23/2002 | CA2429329A1 Bombesin receptor antagonists |
| 05/23/2002 | CA2429195A1 Immunoglobulin superfamily proteins |
| 05/23/2002 | CA2429144A1 Periplasmic domain of an enterobacterium omp protein and its use as carrier or adjuvant |
| 05/23/2002 | CA2428850A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/23/2002 | CA2428837A1 Microspheres of pancreatic enzymes with high stability |
| 05/23/2002 | CA2428805A1 Method for optimally delivering virus to a solid tumor mass |
| 05/23/2002 | CA2428754A1 Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| 05/23/2002 | CA2428709A1 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 05/23/2002 | CA2428527A1 (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors |
| 05/23/2002 | CA2428519A1 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 05/23/2002 | CA2428249A1 Combination therapy for estrogen-dependent disorders |
| 05/23/2002 | CA2427902A1 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 05/23/2002 | CA2427896A1 Carrier vectors through an epithelium with tight junctions |
| 05/23/2002 | CA2426089A1 Bombesin receptor antagonists |
| 05/23/2002 | CA2425117A1 Dibenzoxazepine alpha v integrin receptor antagonist |
| 05/22/2002 | EP1207203A2 DNA sequence and papillomavirus vaccine |
| 05/22/2002 | EP1207199A1 Tumor antigen |
| 05/22/2002 | EP1206941A1 Activity potentiators for chemotherapeutics, anticancer compositions and method for potentiating the activity of chemotherapeutics |
| 05/22/2002 | EP1206574A2 Guanidinium functionalized oligomers and methods |
| 05/22/2002 | EP1206573A1 26 human secreted proteins |
| 05/22/2002 | EP1206563A1 Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof |
| 05/22/2002 | EP1206562A2 Genetically engineered cell lines, and their uses, in particular for neurotoxicity testing |
| 05/22/2002 | EP1206555A1 F v? antibody construct comprising binding sites for a cd16 receptor and a cd30 surface protein |
| 05/22/2002 | EP1206553A2 Isomerase proteins |
| 05/22/2002 | EP1206544A2 Odorant-binding human proteins fixing hydrophobic ligands: polypeptides and polynucleotides coding for said polypeptides and uses thereof |
| 05/22/2002 | EP1206543A2 Membrane associated proteins |
| 05/22/2002 | EP1206541A1 Dendritic enriched secreted lymphocyte activation molecule |
| 05/22/2002 | EP1206539A2 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| 05/22/2002 | EP1206535A1 Tumor-associated antigen (r11) |
| 05/22/2002 | EP1206529A2 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-BETA 1,3-N-ACETYLGALACTOSAMINE-ALPHA-R/(GlcNAc to GalNAc) BETA 1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3 |
| 05/22/2002 | EP1206527A1 Treatment of inflammatory or malignant disease using dnazymes |
| 05/22/2002 | EP1206491A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 05/22/2002 | EP1206487A2 Notch receptor ligands and uses thereof |
| 05/22/2002 | EP1206485A2 New effectors of dipeptidyl peptidase iv for topical use |
| 05/22/2002 | EP1206480A2 Methods of obtaining 2-methoxyestradiol of high purity |
| 05/22/2002 | EP1206478A1 Antisense modulation of mekk5 expression |
| 05/22/2002 | EP1206474A1 Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| 05/22/2002 | EP1206473A1 Isomeric fused pyrrolocarbazoles and isoindolones |
| 05/22/2002 | EP1206467A1 N-heterocyclic derivatives as nos inhibitors |
| 05/22/2002 | EP1206462A2 Heterocyclic compounds inhibiting angiogenesis |
| 05/22/2002 | EP1206455A1 ALPHAvBETA3 INTEGRIN INHIBITORS |
| 05/22/2002 | EP1206454A1 NOVEL INTEGRIN ALPHAvBETA3 INHIBITORS |
| 05/22/2002 | EP1206452A2 Novel method for preparing benzoperhydroisoindole compounds |
| 05/22/2002 | EP1206448A1 Novel vitamin d analogues |